IE
PMN icon

Israel Englander’s ProMIS Neurosciences PMN Stock Holding History

Israel Englander’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$738K Sell
56,045
-21,876
-28% -$237K ﹤0.01% 4527
2026
Q1 		$990K Buy
+77,921
New +$1.16M ﹤0.01% 4401

Other funds holding PMN

JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Israel Englander's PMN Position: Q2 2026 in Review

Israel Englander reduced its ProMIS Neurosciences (PMN) stake by 28% in Q2 2026, selling an estimated $237K and leaving 56,045 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #4527.

Israel Englander first reported a position in PMN in Q1 2026 and has held it in 2 quarters since. The position peaked at $990K in Q1 2026. 27 funds tracked by Wall St. Rank hold PMN as of Q2 2026.

  • Israel Englander held 56,045 shares of ProMIS Neurosciences worth $738K as of Q2 2026.
  • Israel Englander sold 21,876 ProMIS Neurosciences shares in Q2 2026, an estimated $237K.
  • ProMIS Neurosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4527 holding.
  • Israel Englander first reported a position in ProMIS Neurosciences in Q1 2026 and has held it in 2 quarters since.
  • Israel Englander's ProMIS Neurosciences position peaked at $990K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.